

Gregory Louie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3960246/publications.pdf>

Version: 2024-02-01

20
papers

1,654
citations

686830

13
h-index

940134

16
g-index

23
all docs

23
docs citations

23
times ranked

2462
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome. <i>Alzheimer's and Dementia</i> , 2019, 15, 76-92.	0.4	396
2	Metabolic network failures in Alzheimer's disease: A biochemical road map. <i>Alzheimer's and Dementia</i> , 2017, 13, 965-984.	0.4	362
3	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. <i>Alzheimer's and Dementia</i> , 2019, 15, 232-244.	0.4	198
4	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. <i>JAMA Network Open</i> , 2019, 2, e197978.	2.8	142
5	Sex and APOE ϵ 4 genotype modify the Alzheimer's disease serum metabolome. <i>Nature Communications</i> , 2020, 11, 1148.	5.8	115
6	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. <i>Cell Reports Medicine</i> , 2020, 1, 100138.	3.3	102
7	Generation and quality control of lipidomics data for the Alzheimer's disease neuroimaging initiative cohort. <i>Scientific Data</i> , 2018, 5, 180263.	2.4	55
8	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , 2019, 9, 173.	2.4	53
9	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. <i>Scientific Data</i> , 2017, 4, 170140.	2.4	49
10	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. <i>Translational Psychiatry</i> , 2021, 11, 153.	2.4	46
11	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	2.0	36
12	Peripheral serum metabolomic profiles inform central cognitive impairment. <i>Scientific Reports</i> , 2020, 10, 14059.	1.6	25
13	Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. <i>Brain Communications</i> , 2021, 3, fcb139.	1.5	21
14	Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 149.	3.0	19
15	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. <i>Scientific Data</i> , 2019, 6, 212.	2.4	15
16	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, 926.	1.4	15
17	Transcriptomics, metabolomics, lipidomics, metabolic flux and mGWAS analyses of sphingolipid pathway highlights novel drugs for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
18	Investigating the importance of acylcarnitines in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e056647.	0.4	1

#	ARTICLE	IF	CITATIONS
19	F3â€1: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.4	0
20	Serum metabolome informs neuroimaging biomarkers for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045596.	0.4	0